Few endocrine systems are studied as continuously as the growth hormone axis. It is one of the oldest characterized neuroendocrine feedback loops, and it remains a reference framework for anyone building a research library around growth-hormone-releasing peptides. The axis is compact but layered: a hypothalamic trigger, a pituitary amplifier, a peripheral effector, and two feedback…

Few receptors in modern metabolic research are studied as intensively as the glucagon-like peptide-1 receptor (GLP-1R). It sits at the center of an entire class of engineered peptides — from the native hormone itself through single-, dual-, and triple-receptor analogs — and it has become one of the most structurally characterized class B G-protein-coupled receptors…

Few comparisons in incretin-receptor research draw as much attention as retatrutide versus tirzepatide. Both are synthetic 39-residue peptides engineered by the same discovery lineage, both carry a fatty-diacid modification for extended half-life, and both act on the incretin-receptor family. The defining difference is receptor breadth: tirzepatide engages two receptors, retatrutide engages three. For research groups…

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) has finished its two-day peptide review, and the final scorecard is now complete. Over July 23–24, 2026, the committee recommended six of the seven peptides it evaluated for inclusion on the Section 503A Bulk Drug Substances List — and rejected one. In doing so it overrode its own…

“Best research peptides” is a phrase that means something very specific once you strip away the marketing. It does not mean the peptides with the most impressive anecdotes or the loudest vendor copy. In a laboratory context, the peptides worth knowing are the ones with a defined molecular identity, a mechanism described at the receptor…

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) did something the agency’s own scientists had recommended against: it voted to recommend four peptides — BPC-157, KPV, TB-500, and MOTS-c — for addition to the 503A Bulks List for pharmacy compounding. The FDA’s pre-meeting briefing documents had proposed the same conclusion for every…

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) did something its own agency’s scientists had recommended against: it voted 8-6, with one abstention, to recommend that two peptides — BPC-157 and KPV — be added to the 503A Bulks List for pharmacy compounding. Coming just one day after the FDA’s published briefing…

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets at the agency’s White Oak campus to consider whether seven peptides should be added to the 503A Bulks List for pharmacy compounding. Ahead of that meeting, the FDA published a briefing document for each substance — and across all seven, the…

Survodutide, known in the development literature as BI 456906, is a synthetic glucagon-based peptide engineered to act at two receptors at once — the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It belongs to a class of molecules sometimes called “unimolecular dual agonists”: single peptides designed to engage more than one metabolic receptor…

Cagrilintide is a synthetic, long-acting amylin analogue, and it belongs to a class of research molecules that has drawn intense interest precisely because of the receptor system it engages rather than any single downstream endpoint. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin, and its receptors are among the more unusual constructs in G…